Frequency of Tuberculosis in Psoriasis Patients

Completed

• Conditions: Psoriasis Vulgaris; Tuberculosis

• Registration Number: NCT06563635
• Lead Sponsor: Bezmialem Vakif University

Brief Summary

Aim of this study is evaluation of patients receiving TNF inhibitor therapy in terms of tuberculosis at the end of 15 years in a single center.

Detailed Description

Aim of this study is evaluation of patients receiving TNF inhibitor therapy in terms of tuberculosis at the end of 15 years in a single center. TNF inhibitor therapy may increase the risk for tuberculosis infection. According to medical data in our hospital in last 15 years, tuberculosis rate of psoriasis patients receiving etanercept, adalimumab and infliximab will be compared.

Study Timeline

• Study Start: 2023-05-01
• Primary Completion: 2023-07-31
• Study Completion: 2023-07-31
• Study First Submitted: 2023-08-31
• Status Verified: 2024-08
• Study First Submitted QC: 2024-08-19
• Last Update Submitted: 2024-08-19
• Study First Posted: 2024-08-21
• Last Update Posted: 2024-08-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 719

Inclusion Criteria

• psoriasis patients receiving TNF inhibitor therapy

Exclusion Criteria

• patients without TNF inhibitor therapy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
tuberculosis rate	patients from June 2007 to January 2023, up to 15 years	number of patients with tuberculosis infection after receiving TNF inhibitor therapy

Trial Locations

Locations (1)

Bezmialem Vakif University Hospital; 🇹🇷 Istanbul, Turkey